Congress denounces FDA’s Aduhelm approval as ‘riddled with irregularities’
U.S. health officials’ approval process for Biogen Inc.’s controversial Alzheimer’s drug was “full of irregularities,” raising serious concerns about breaches of protocol at the agency, officials said. Congressional investigators. The Food and Drug Administration overly cooperated with Biogen in evaluating the drug, called Aduhelm, according to the report of an 18-month investigation released Thursday by …
Congress denounces FDA’s Aduhelm approval as ‘riddled with irregularities’ Read More »
